Compare IDR & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IDR | PACB |
|---|---|---|
| Founded | 1996 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Laboratory Analytical Instruments |
| Sector | Basic Materials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 502.0M | 462.8M |
| IPO Year | 2000 | 2010 |
| Metric | IDR | PACB |
|---|---|---|
| Price | $35.48 | $1.41 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $1.67 |
| AVG Volume (30 Days) | 210.3K | ★ 5.4M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 70.15 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | $42,406,253.00 | ★ $93,468,000.00 |
| Revenue This Year | $25.52 | $11.32 |
| Revenue Next Year | N/A | $12.14 |
| P/E Ratio | $90.43 | ★ N/A |
| Revenue Growth | ★ 64.59 | 3.04 |
| 52 Week Low | $12.40 | $1.09 |
| 52 Week High | $54.70 | $2.73 |
| Indicator | IDR | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 44.81 | 50.86 |
| Support Level | $33.59 | $1.18 |
| Resistance Level | $41.05 | $1.78 |
| Average True Range (ATR) | 2.85 | 0.12 |
| MACD | 0.29 | -0.00 |
| Stochastic Oscillator | 33.73 | 22.34 |
Idaho Strategic Resources Inc is a vertically integrated, operating junior mining company. The Company's primary business is exploring for, developing, and extracting gold, and to a lesser extent, silver, and base metal mineral resources in the greater Coeur d'Alene Mining District of North Idaho. The Company produces gold at the Golden Chest Mine located in the Murray Gold Belt area of the world-class Coeur d'Alene Mining District, north of the prolific Silver Valley.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.